Literature DB >> 19190878

Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.

Elham Shahgholi1, Parvaneh Vosough, Kambiz Sotoudeh, Khadijeh Arjomandi, Shahla Ansari, Soraya Salehi, Mohammad Faranoush, Mohammad Ali Ehsani.   

Abstract

OBJECTIVE: The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP).
METHODS: Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single dose intravenous 75 microg/kg anti-D or 1g/kg IVIG for two consecutive days (total dose 2 g/kg). Response rate defined as a platelet count over 20,000 / microL 72 hours after initial treatment.
RESULTS: Eighty one patients (52 male and 29 female) with mean age of 5 years and 3 months randomly divided in anti-D group (n=42) and IVIG group (n=39). Mean baseline (pretreatment) platelet counts were 15406 / microL and 15230/ microL in anti-D and IVIG group, respectively. The response rate in IVIG group (98%) was more significant than anti-D group (76%); (P = 0.017). After 7 days the platelet counts of all patients in IVIG group were more than 20,000/ microL while in anti-D group 12% had platelet counts below 20,000/ microL.
CONCLUSION: In acute childhood ITP, initial treatment with IVIG (2g/Kg in divided dose) increased platelet count more rapidly and more significant than intravenous anti-D (single dose of 75 microg/kg) within the first 72 hours.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190878     DOI: 10.1007/s12098-008-0243-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  21 in total

Review 1.  Immune thrombocytopenic purpura.

Authors:  Douglas B Cines; Victor S Blanchette
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.

Authors: 
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

3.  Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.

Authors:  I Warrier; J B Bussel; L Valdez; J Barbosa; D S Beardsley
Journal:  J Pediatr Hematol Oncol       Date:  1997 May-Jun       Impact factor: 1.289

4.  Idiopathic thrombopenic purpura in childhood.

Authors:  W A NEWTON; W W ZUELZER
Journal:  N Engl J Med       Date:  1951-12-06       Impact factor: 91.245

5.  Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

Authors:  V Blanchette; P Imbach; M Andrew; M Adams; J McMillan; E Wang; R Milner; K Ali; D Barnard; M Bernstein
Journal:  Lancet       Date:  1994-09-10       Impact factor: 79.321

Review 6.  Intravenous Rh immune globulin for treating immune thrombocytopenic purpura.

Authors:  S G Sandler
Journal:  Curr Opin Hematol       Date:  2001-11       Impact factor: 3.284

7.  Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001.

Authors:  Sara K Vesely; George R Buchanan; Leah Adix; James N George; Alan R Cohen; Victor S Blanchette; Thomas Kühne
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

8.  Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect.

Authors:  J B Bussel; J N Graziano; R P Kimberly; S Pahwa; L M Aledort
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

9.  Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial.

Authors:  Martin Benesch; Reinhold Kerbl; Herwig Lackner; Andrea Berghold; Wolfgang Schwinger; Karin Triebl-Roth; Christian Urban
Journal:  J Pediatr Hematol Oncol       Date:  2003-10       Impact factor: 1.289

Review 10.  Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on.

Authors:  P Bierling; B Godeau
Journal:  Vox Sang       Date:  2004-01       Impact factor: 2.144

View more
  5 in total

Review 1.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

2.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

3.  Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.

Authors:  Muhittin Celik; Ali Bulbul; Gönül Aydogan; Deniz Tugcu; Emrah Can; Sinan Uslu; Mesut Dursun
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

4.  Guidelines on the treatment of primary immune thrombocytopenia in children and adolescents: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2012.

Authors:  Sandra Regina Loggetto; Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Wanderley Marques Bernardo; Leticia Medeiros; Andrea Thives de Carvalho Hoepers
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 5.  Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Authors:  Jun Ho Jang; Ji Yoon Kim; Yeung-Chul Mun; Soo-Mee Bang; Yeon Jung Lim; Dong-Yeop Shin; Young Bae Choi; Ho-Young Yhim; Jong Wook Lee; Hoon Kook
Journal:  Blood Res       Date:  2017-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.